- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- 【Updated on June 30, 2025】Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Observational data for comparative effectiveness research: An emulation of randomised trials of statins and primary prevention of coronary heart disease
-
- Goodarz Danaei
- Department of Epidemiology, Harvard School of Public Health, Boston, USA
-
- Luis A García Rodríguez
- Centro Español de Investigación Farmacoepidemiológica, Madrid, Spain
-
- Oscar Fernández Cantero
- Centro Español de Investigación Farmacoepidemiológica, Madrid, Spain
-
- Roger Logan
- Department of Epidemiology, Harvard School of Public Health, Boston, USA
-
- Miguel A Hernán
- Department of Epidemiology, Harvard School of Public Health, Boston, USA
Search this article
Description
<jats:p> This article reviews methods for comparative effectiveness research using observational data. The basic idea is using an observational study to emulate a hypothetical randomised trial by comparing initiators versus non-initiators of treatment. After adjustment for measured baseline confounders, one can then conduct the observational analogue of an intention-to-treat analysis. We also explain two approaches to conduct the analogues of per-protocol and as-treated analyses after further adjusting for measured time-varying confounding and selection bias using inverse-probability weighting. As an example, we implemented these methods to estimate the effect of statins for primary prevention of coronary heart disease (CHD) using data from electronic medical records in the UK. Despite strong confounding by indication, our approach detected a potential benefit of statin therapy. The analogue of the intention-to-treat hazard ratio (HR) of CHD was 0.89 (0.73, 1.09) for statin initiators versus non-initiators. The HR of CHD was 0.84 (0.54, 1.30) in the per-protocol analysis and 0.79 (0.41, 1.41) in the as-treated analysis for 2 years of use versus no use. In contrast, a conventional comparison of current users versus never users of statin therapy resulted in a HR of 1.31 (1.04, 1.66). We provide a flexible and annotated SAS program to implement the proposed analyses. </jats:p>
Journal
-
- Statistical Methods in Medical Research
-
Statistical Methods in Medical Research 22 (1), 70-96, 2011-10-19
SAGE Publications
- Tweet
Details 詳細情報について
-
- CRID
- 1363670318190331776
-
- ISSN
- 14770334
- 09622802
-
- Data Source
-
- Crossref